The PennZone

  • Home
  • Non-profit
  • Music
  • Marketing
  • Books
  • Entertainment
  • Legal
  • Health
  • Automotive

ExpressCells Named Most Fundable Company by Pepperdine Graziadio Business School
The PennZone/10088820

Trending...
  • Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
PHILADELPHIA - PennZone -- ExpressCells, Inc., a biotechnology company that creates advanced cell lines for research, was awarded a silver designation on the Pepperdine Graziadio Business School's third annual Most Fundable Companies® List. ExpressCells competed against over 4,500 early-stage U.S. startups spanning all 50 states, all with less than $10 million in annual revenue, to be named among a list of twenty. The Most Fundable Companies initiative is designed to recognize exceptional entrepreneurs who are solving today's problems with inventive solutions and are also seeking investment capital to fuel their company's growth.

"Since starting ExpressCells in 2018, we've been focused on helping biological researchers conduct better experiments.. The Most Fundable Companies initiative provided us with a data-driven analysis that we have already incorporated into our fundraising activities," said Matt Handel, CEO. "It's validating that Pepperdine Graziadio Business School recognizes entrepreneurs throughout the country and provides resources to assist startups in securing private capital to accelerate meaningful innovation across industries and communities."

More on The PennZone
  • Champions for Education to Honor United Way of the Greater Lehigh Valley and Induct Three Leaders
  • Holiday Gambling Spending Expected to Rise 12% in December
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • Free Senior Housing Webinar Helps Families Plan for Aging Before a Crisis Forces Difficult Decisions
  • Claude Zdanow named Managing Director in Miami, Florida

The Most Fundable Companies initiative involved a multi-phase assessment that evaluated several company variables, including financial projections, market opportunity, intellectual property, and the strength of the management team, all of which were used to produce a fundability score. The Most Fundable Companies were evaluated and selected based on their readiness for private investment. Most Fundable Companies is powered by The Venture Alliance.

As a winner on the Most Fundable Companies List, ExpressCells will be profiled on Entrepreneur.com and be featured in the December print issue of the magazine. For a complete list of the winners, visit www.pepperdine.edu/mfc-list, where you can vote for ExpressCells as the "crowd favorite" through November 1.

The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It neither constitutes investment advice, nor is an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.

More on The PennZone
  • YWCA Hanover Celebrates Opening of New Children's Learning Academy
  • Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
  • netElastic Announces vBNG And CGNAT 2.0 General Availability
  • Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
  • Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its uses it proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other biological research. It shortens the time for delivery of knock-in cell lines by up to 75% relative to current technologies. The speed of the process allows ExpressCells to insert one to three genes into the same cell line. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines.

ExpressCells' genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit xpresscells.com (http://www.xpresscells.com/).

Contact
Matt Handel
***@xpresscells.com


Source: ExpressCells

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
  • Dutch Mill Bulbs Launches Pink Ribbon Tulip Fundraise ~ National Breast Cancer Foundation, Inc.®
  • SecureMaine 2026 is Here -- Thursday October 8th!
  • Bluestone Laundromat Makes a Difference in the Archbald Community
  • HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
  • Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • BJJ App mmaGPT Expands Academy Program to Support Jiu-Jitsu Instructors with AI Technique Coaching
  • Ten Ten Ten Announces Maximizing Clinical Operations
  • Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
  • CardsNearby Launches Free Nationwide Directory of Card Shows and Local Card Shops for Collectors
  • American Garden Rose Selections™ Announces 2027 Winners
  • Crossroads4Hope Launches Blood Cancer Resource Hub
  • Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • Georgia's Magical Nights of Lights Bigger and Brighter for 2026
  • Bicentennial Occult Outing Alternative History Video Series Launches for Spooky Season
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors

Popular on PennZone

  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • The Culture and Travel Report Enters a New Chapter as Travel and Hospitality Brands Take Notice
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service

Similar on PennZone

  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us